Portsmouth recruit first global to respiratory study
The respiratory research team at Portsmouth Hospitals NHS Trust have recruited the first patient into a global study exploring the effectiveness of biologics for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA).
Finding the right patient for a clinical trial is always challenging and with EGPA being a rare disease, with an incidence of less than 1 in 250,000 patients, recruiting the first global patient is a great achievement.
Dr Hitasha Rupani, the principal investigator for the study in Portsmouth, said: “We achieved this by very careful and robust feasibility and an all-round team effort. We also worked closely with industry partners to bring this excellent opportunity to our patients who would otherwise receive toxic treatments with significant side effects.”
The MANDARA study is a randomised, double-blind, active-controlled study looking at the efficacy of Benralizumab compared to Mepolizumab for patients with EGPA. The Portsmouth research team would be happy to hear from clinicians across Wessex who may have patients with this condition.
